乳腺癌早期筛查和诊断生物标志物研究进展

Biomarkers for early screening and diagnosis of breast cancer:a review

2020年全球乳腺癌(breast cancer,BC)新发病例达226万例,占全部肿瘤新发病例的11.7%,是全世界发病率最高的癌症。早期发现、早期诊断和早期治疗是降低乳腺癌死亡率及改善预后的关键。尽管乳房X光筛查被广泛用作乳腺癌筛查的工具,但其假阳性、辐射性和过度诊断仍是亟待解决的问题。因此,亟需开发易于获取且稳定可靠的生物标志物,用于乳腺癌无创筛查和诊断。近年来多项研究显示来自乳腺癌患者血液中的循环肿瘤细胞DNA(circulating tumor cell DNA,ctDNA)、癌胚抗原(carcinoembryonic antigen,CEA)、糖类抗原15-3(carbohydrate antigen 15-3,CA15-3)、细胞外囊泡(extracellular vesicles,EV)、循环miRNA和BRCA基因突变等生物标志物,以及来自人体尿液、呼出气体(volatile organic compounds,VOCs)和乳头吸出液(nipple aspirate fluid,NAF)中的磷脂、miRNA、苯乙酮和十六烷等多种生物标志物与乳腺癌早期筛查和诊断密切相关。本文综述了上述生物标志物在乳腺癌早期筛查和诊断中的应用。

The estimated new cases of breast cancer(BC)patients were 2.26 million in 2020,which accounted for 11.7%of all cancer patients,making it the most prevalent cancer worldwide.Early detection,diagnosis and treatment are crucial to reduce the mortality,and improve the prognosis of BC patients.Despite the widespread use of mammography screening as a tool for BC screening,the false positive,radiation,and overdiagnosis are still pressing issues that need to be addressed.Therefore,it is urgent to develop accessible,stable,and reliable biomarkers for non-invasive screening and diagnosis of BC.Recent studies indicated that the circulating tumor cell DNA(ctDNA),carcinoembryonic antigen(CEA),carbohydrate antigen 15-3(CA15-3),extracellular vesicles(EV),circulating miRNAs and BRCA gene from blood,and the phospholipid,miRNAs,hypnone and hexadecane from urine,nipple aspirate fluid(NAF)and volatile organic compounds(VOCs)in exhaled gas were closely related to the early screening and diagnosis of BC.This review summarizes the advances of the above biomarkers in the early screening and diagnosis of BC.